{"artifact":{"id":"rsc-h-9bcba57f3f-f10202db","artifact_type":"rigor_score_card","entity_ids":null,"title":"Rigor Score Card: VPS35 retromer activation prevents endosomal tau templating across all brain regions and disease sta","quality_score":0.25,"created_by":"rigor_score_card","provenance_chain":"[{\"artifact_id\": \"h-9bcba57f3f\", \"relation\": \"scores\"}]","content_hash":null,"metadata":{"dimensions":["scientific_premise","study_design","blinding","power_analysis","resource_identification","statistical_reporting","data_availability","sabv"],"eval_a_raw":{"scores":{"sabv":{"score":1,"evidence":"This mechanism operates pan-cortically and across disease stages, making it the most broadly applicable therapeutic target.","location":"Sentence 3"},"blinding":{"score":1,"evidence":"The R33 small-molecule activator series provides a pharmacologically tractable entry point that is investment-ready.","location":"Sentence 2"},"study_design":{"score":1,"evidence":"This mechanism operates pan-cortically and across disease stages","location":"Sentence 3"},"power_analysis":{"score":1,"evidence":"making it the most broadly applicable therapeutic target.","location":"Sentence 3"},"data_availability":{"score":1,"evidence":"that is investment-ready.","location":"Sentence 2"},"scientific_premise":{"score":2,"evidence":"Retromer dysfunction creates a permissive early endosome compartment where low pH and molecular crowding promote tau fibrillization","location":"Sentence 1"},"statistical_reporting":{"score":1,"evidence":"amplifying propagation regardless of the primary release mechanism","location":"Sentence 1"},"resource_identification":{"score":2,"evidence":"The R33 small-molecule activator series provides a pharmacologically tractable entry point","location":"Sentence 2"}},"overall_summary":"This text represents a promotional synopsis lacking any methodological content. All eight dimensions receive deficient scores (1-2) due to absence of study design, statistical methods, resource identification, or reporting standards. No citations to prior work, no ARRIVE/MDAR compliance indicators, and no mention of sex as a biological variable.","weakest_dimension":"study_design (score 1) - No study design described; text reads as mechanism summary with commercial framing ('investment-ready') rather than scientific methods section","strongest_dimension":"resource_identification (score 2) - R33 activator series is named, though without RRID or catalog identifiers"},"eval_b_raw":{"scores":{"sabv":{"score":1,"evidence":"This mechanism operates pan-cortically and across disease stages","location":"Source text, paragraph 1"},"blinding":{"score":1,"evidence":"amplifying propagation regardless of the primary release mechanism","location":"Source text, paragraph 1"},"study_design":{"score":1,"evidence":"This mechanism operates pan-cortically and across disease stages","location":"Source text, paragraph 1"},"power_analysis":{"score":1,"evidence":"The R33 small-molecule activator series provides a pharmacologically tractable entry point that is investment-ready","location":"Source text, paragraph 1"},"data_availability":{"score":1,"evidence":"Retromer dysfunction creates a permissive early endosome compartment","location":"Source text, paragraph 1"},"scientific_premise":{"score":1,"evidence":"Retromer dysfunction creates a permissive early endosome compartment where low pH and molecular crowding promote tau fibrillization","location":"Source text, paragraph 1"},"statistical_reporting":{"score":1,"evidence":"making it the most broadly applicable therapeutic target","location":"Source text, paragraph 1"},"resource_identification":{"score":1,"evidence":"The R33 small-molecule activator series","location":"Source text, paragraph 1"}},"overall_summary":"This source text contains zero methodological information, citing no prior work, no experimental design, no statistical methods, no resource identifiers (RRIDs), no data/code sharing plans, no power analysis, and no consideration of sex as a biological variable. It presents speculative mechanistic claims as established fact and reads as promotional 'investment-ready' language rather than scientific reporting.","weakest_dimension":"All dimensions are equally deficient; no dimension achieves score >1","strongest_dimension":"scientific_premise"},"provider_a":"minimax","provider_b":"glm","reconciled":{"reconciler_notes":"Both evaluators independently identified the source text as promotional/marketing material lacking methodological content. Minor score differences on scientific_premise (2 vs 1) and resource_identification (2 vs 1) were within the |≤1| threshold, so averages were taken per protocol. All evidence quotes exceed 10 characters and are valid. Both evaluators converged on the absence of study design, statistical methods, RRIDs, power analysis, and SABV consideration. No dimensions received scores >2, confirming this text is unsuitable as standalone scientific documentation.","overall_agreement":"high","reconciled_scores":{"sabv":{"score":1,"a_score":1,"b_score":1,"a_evidence":"This mechanism operates pan-cortically and across disease stages, making it the most broadly applicable therapeutic target.","b_evidence":"This mechanism operates pan-cortically and across disease stages","disagreement":false},"blinding":{"score":1,"a_score":1,"b_score":1,"a_evidence":"The R33 small-molecule activator series provides a pharmacologically tractable entry point that is investment-ready.","b_evidence":"amplifying propagation regardless of the primary release mechanism","disagreement":false},"study_design":{"score":1,"a_score":1,"b_score":1,"a_evidence":"This mechanism operates pan-cortically and across disease stages","b_evidence":"This mechanism operates pan-cortically and across disease stages","disagreement":false},"power_analysis":{"score":1,"a_score":1,"b_score":1,"a_evidence":"making it the most broadly applicable therapeutic target.","b_evidence":"The R33 small-molecule activator series provides a pharmacologically tractable entry point that is investment-ready","disagreement":false},"data_availability":{"score":1,"a_score":1,"b_score":1,"a_evidence":"that is investment-ready.","b_evidence":"Retromer dysfunction creates a permissive early endosome compartment","disagreement":false},"scientific_premise":{"score":2,"a_score":2,"b_score":1,"a_evidence":"Retromer dysfunction creates a permissive early endosome compartment where low pH and molecular crowding promote tau fibrillization","b_evidence":"Retromer dysfunction creates a permissive early endosome compartment where low pH and molecular crowding promote tau fibrillization","disagreement":false},"statistical_reporting":{"score":1,"a_score":1,"b_score":1,"a_evidence":"amplifying propagation regardless of the primary release mechanism","b_evidence":"making it the most broadly applicable therapeutic target","disagreement":false},"resource_identification":{"score":2,"a_score":2,"b_score":1,"a_evidence":"The R33 small-molecule activator series provides a pharmacologically tractable entry point","b_evidence":"The R33 small-molecule activator series","disagreement":false}},"inter_rater_agreement":"N/A (Cohen's kappa inappropriate for ordinal scale with n=2 raters; raw agreement = 75%)","dimensions_with_disagreement":[]},"_schema_version":1,"scored_entity_id":"h-9bcba57f3f","scored_entity_type":"hypothesis","scored_entity_title":"VPS35 retromer activation prevents endosomal tau templating across all brain regions and disease stages"},"created_at":"2026-04-22T14:11:22.337497-07:00","updated_at":"2026-04-22T14:11:22.337500-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-22T14:11:22.337497-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"429a47e1-c64d-4957-80a7-896cb4fc15f7","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"rigor_score_card"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"rsc-h-9bcba57f3f-f10202db","is_canonical":true,"supersede_chain":["rsc-h-9bcba57f3f-f10202db"]}